Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy [4]

Haematologica

Volumn 87, Issue 10, 2002, Pages 1114-1116

  Giles, Francis ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Thomas, Deborah ^a   Kantarjian, Hagop ^a   Estey, Elihu ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute myeloid leukemia; Hepatic veno occlusive disease; Mylotarg ; Ursodiol

Indexed keywords

ALTEPLASE; CALICHEAMICIN; CYCLOSPORIN; CYTARABINE; DEFIBROTIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HEPARIN; INTERLEUKIN 11; RETINOIC ACID; TROXACITABINE; URSODEOXYCHOLIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FUNCTION; LETTER; LIVER FUNCTION; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BILIRUBIN; CHOLAGOGUES AND CHOLERETICS; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOTOXINS; LIVER DISEASES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 0036800477     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406-13.
2. Stadtmauer E, Larson R, Sievers E, Estey E, Löwenberg B, Leopold L, et al. Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg, CMA-676). Blood 2001; 98:520 [abstract].
3. Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Sill H, Linkesch W. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol 2001; 80:119-20.
4. Lech JA, Rossetti J, Lister J, Raymond JR, Ziegler Z, Gryn JF, et al. Hepatic venoocclusive disease as a complication of Mylotarg (gemtuzumab ozogamicin): The Western Pennsylvania Cancer Institute experience. Blood 2001; 98:202 [abstract].
5. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002; 99:2310-4.
6. Langston A, Fienstein B, Hutcherson D, Heffner LT, Redei I, Smith K, et al. Non-fatal veno-occlusive disease in nontransplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin). Blood 2001; 98:201 [abstract].
7. Kell JW, Burnett AK, Chopra R, Yin J. Effects of Mylotarg (gemtuzumab ozogomycin) in combination with standard induction chemotherapy in the treatment of acute myeloid leukaemia: A feasibility study [abstract]. Blood 2001; 98: 123.
8. De Angelo D, Russo D, Castaigne S, Esteve J, Burnett A, Goldstone A, et al. Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia. Blood 2001; 98:199 [abstract].
9. Amadori S, Willemze R, Suciu S, Mandelli F, Selleslag D, Stauder R, et al. Sequential administration of gemtuzumab ozogamicin and intensive chemotherapy for remission induction in previously untreated patients with AML over the age of 60: Interim results of the EORTC leukemia group AML-A phase II trial. Blood 2001; 98:587[abstract].
10. Bearman SI. Veno-occlusive disease of the liver. Curr Opin Oncol 2000; 12:103-9.